Lonza to Highlight Innovative Capsugel® Capsule Technologies at CPhI Worldwide 2019

October 10, 2019

Basel, Switzerland, 10 October 2019 – Capsule Delivery Solutions (CDS), part of Lonza Pharma & Biotech, will showcase its diverse portfolio of Capsugel® capsules and technologies designed to support drug development at the annual CPhI Worldwide 2019, taking place in Frankfurt on November 5-7. 

“In today’s challenging pharmaceutical world, our customers are looking for performance and innovation to better address the demands of connected patients and consumers, who are more involved in their healthcare choices than ever before,” says Sara Lesina, Global Marketing Director, Lonza. “By listening closely to what our customers need, we are developing new cutting-edge solutions for encapsulated dosage forms using the technology platforms that most improve patients’ health now and in the future.” 

The comprehensive portfolio of CDS products and technologies will be on display at booth A70 in Hall 10.2, including:

  • The newly launched Capsugel® Zephyr™ Portfolio, an end-to-end inhalation drug development and manufacturing service specifically tailored for pulmonary drug delivery. The Zephyr™ dry-powder inhalation (DPI) capsule portfolio spans particle engineering – including micronization and spray-draying – formulation and encapsulation.
  • The Lonza Engine™ comprehensive equipment portfolio designed to address customer needs throughout the entire drug development process for small molecules, including micronization and Xcelodose® powder-in-capsule filling.
  • The company’s HPMC Capsugel® capsule portfolio, including the flagship product Vcaps® Plus, which is manufactured without the use of gelling agents.
  • The OTC Capsugel® capsule portfolio, including Press-Fit® capsules for effective formulation of non-prescription drug products.
  • The company’s R&D offering, including DBcaps® and Colorista® capsules, designed specifically to enhance clinical trials and speed up drug product development.

“We continue to lead the industry in driving innovative solutions for capsule delivery technologies,” says Stef Vanquickenborne, VP R&D, Lonza. “Combining our knowledge of excipients, drug products and drug services, we offer integrated solutions to address the entire spectrum of drug development challenges for small and large molecules.” 

CDS’s subject matter experts will participate in three CPhI Worldwide Pharma Insight Briefing speaking sessions focused on DPI innovation, Quality by Design and the Lonza Engine™ equipment portfolio:

  • Tuesday 5 November, 13:10, CPhI Theatre 61D61: Frédérique Bordes-Picard – Leading the way in capsule-based DPIs through customization with the Capsugel® Zephyr™ Portfolio
  • Wednesday 6 November, 13:50, CPhI Theatre 61D61: Karin Schrooten – Quality by Design and continuous improvement as a basis for high product quality
  • Wednesday 6 November, 15:10, CPhI Theatre, 61D61: Mattia Wiedemeier – Lonza Engine™ equipment portfolio for small molecule bioavailability enhancement, particle engineering and drug product development.

Additional information about each speaking session is available here

About Lonza's Capsule Delivery Solutions

Capsule Delivery Solutions, part of Lonza Pharma & Biotech, is the global leader in capsules and encapsulation technology and designs. It designs, develops and manufactures Capsugel® capsules, offering the broadest range of capsule polymers, sizes and designs for companies that make branded, generic and specialty pharmaceuticals; biotech products and over-the-counter medicines. Its diverse portfolio of capsule technologies including Vcaps® Plus, the Zephyr™ portfolio of DPI capsules and Coni-Snap® Sprinkle capsules offer the potential for selecting the right capsule for different applications. Capsule Delivery Solutions’ Capsugel® brand represents more than 100 years of experience, excellence and dedication to the pharmaceutical and nutraceutical industries. More information about the Capsugel® product range is available on www.capsugel.com

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. 

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live. 

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com

Lonza Contact Details 

Sara Lesina

Head of Global Marketing

Capsule Delivery Solutions

Tel +32 3 890 05 11


Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. 

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.